Study treatments and interventions
The study drug was administered intravenously within 5 min after randomization. Eligible participants in the tirofiban group received intravenous bolus followed by continuous infusion of tirofiban (10 μg/kg bolus and then 0.15 μg/kg/min maintenance for up to 24 h), participants in the placebo group received saline. A rapid EVT was initiated. It was permitted to use rescue drug when reocclusion of the target artery after EVT was observed in the angiographic suite. The rescue drug was saline placebo in the tirofiban group and tirofiban in the placebo group. Patients who achieved successful reperfusion after use of rescue drug were included in this analysis in addition to those not requiring rescue drug.